BB Biotech returned to profit in 2017. The Swiss investment firm will let shareholders participate in its success.
The biotech investment firm had a profit of 688 million Swiss francs in 2017, after a loss of 802 million a year earlier, the company said in a statement today.
BB Biotech will pay a dividend of 3.30 francs per share, up from 2.75 francs a year ago. The payment corresponds to a yield of 5 percent. BB Biotech introduced its dividend policy in 2013.
BB Biotech’s total share return amounted to 23.1 percent last year. The net asset value increased by 23.4 percent.
